Inhibiton Therapeutics Announces ICA-1 Compound Effective in In-Vitro Testing in Various Cancer Cell Lines
ENGLEWOOD, Colo.--(BUSINESS WIRE)--Dec 4, 2007 - Inhibiton Therapeutics, Inc. (OTC/BB: IHBT) announced today that its ICA-1 compound has been effective in laboratory in-vitro testing in various cancer cell lines. The present work performed under a Co-operative Research and Development Agreement (CRADA) with the Department of Veteran's Affairs (VA) demonstrated that inhibition of the enzyme protein kinase C-iota is a promising means to prevent and treat certain cancers through development of a targeted therapy.Laboratory testing to date has shown that ICA-1 was effective in blocking BE(2)C neuroblastoma cells. It was also found that lower concentrations of ICA-1 were more efficacious in inhibiting the proliferation of 64% and 53% of the neuroblastoma cells when compared to control groups. The effective concentration of ICA-1 was shown to be a minimum of 3-5 fold lower than concentrations published for in-vitro studies of a closely related FDA approved chemotherapeutic drug that was shown to be effective in only 20% of the samples tested. The results to date have shown promise that ICA-1 may have potential as a chemotherapeutic drug to inhibit cancer, especially neuroblastoma.
The Company's research is being performed under the VA CRADA at the James A. Haley Veterans' Hospital in Tampa, Florida, in conjunction with the University of South Florida.
Inhibiton Therapeutics, Inc. is a nominally capitalized development stage company focused on biotechnology research, development and potential commercialization of technologies and products for new cancer therapeutic agents and cancer fighting drugs called targeted therapies. The initial focus of the Company's research is a protocol to investigate the effect of PKC isozymes on the regulation of brain cancer cells, which Inhibiton has been funding since September 2004.
The statements included in this press release concerning predictions of economic performance and management's plans and objectives constitute forward-looking statements made pursuant to the safe harbor provisions of Section 21E of the Securities Exchange Act of 1934, as amended, and Section 27A of the Securities Act of 1933, as amended. These statements involve risks and uncertainties that could cause actual results to differ materially from the forward-looking statements. Any statement containing words such as "believes" "anticipates" "plans" or "expects" and other statements which are not historical facts contained in this release are forward-looking, and these statements involve risks and uncertainties and are based on current expectations. Consequently, actual results could differ materially from the expectations expressed in these forward-looking statements. Reference is made to the Company's filings with the Securities and Exchange Commission for a more complete discussion of such risks and uncertainties.
Contact
Inhibiton Therapeutics, Inc.
Thomas B. Olson, 303-796-8940
